JP2002532079A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002532079A5 JP2002532079A5 JP2000587802A JP2000587802A JP2002532079A5 JP 2002532079 A5 JP2002532079 A5 JP 2002532079A5 JP 2000587802 A JP2000587802 A JP 2000587802A JP 2000587802 A JP2000587802 A JP 2000587802A JP 2002532079 A5 JP2002532079 A5 JP 2002532079A5
- Authority
- JP
- Japan
- Prior art keywords
- mbl
- composition
- isolated
- monoclonal antibody
- accession number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100019384 MBL2 Human genes 0.000 description 58
- 239000000203 mixture Substances 0.000 description 46
- 102000005614 monoclonal antibodies Human genes 0.000 description 30
- 108010045030 monoclonal antibodies Proteins 0.000 description 30
- 230000002401 inhibitory effect Effects 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 20
- 210000004408 Hybridomas Anatomy 0.000 description 17
- 108009000280 Complement Activation Proteins 0.000 description 14
- 102100000306 KLHDC2 Human genes 0.000 description 14
- 230000024203 complement activation Effects 0.000 description 14
- 102000004965 antibodies Human genes 0.000 description 9
- 108090001123 antibodies Proteins 0.000 description 9
- 230000001404 mediated Effects 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 102100011109 MASP1 Human genes 0.000 description 4
- 101700086739 MASP1 Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 200000000020 tissue injury Diseases 0.000 description 4
- 210000004027 cells Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000004962 mammalian cells Anatomy 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003246 Arthritis Diseases 0.000 description 2
- 206010061255 Ischaemia Diseases 0.000 description 2
- 206010025135 Lupus erythematosus Diseases 0.000 description 2
- 208000010125 Myocardial Infarction Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11239098P | 1998-12-15 | 1998-12-15 | |
| US60/112,390 | 1998-12-15 | ||
| PCT/US1999/029919 WO2000035483A1 (en) | 1998-12-15 | 1999-12-15 | Methods and products for regulating lectin complement pathway associated complement activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002532079A JP2002532079A (ja) | 2002-10-02 |
| JP2002532079A5 true JP2002532079A5 (ru) | 2007-02-15 |
Family
ID=22343639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000587802A Pending JP2002532079A (ja) | 1998-12-15 | 1999-12-15 | 補体活性化に関連するレクチン補体経路を調節するための方法および産物 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1140171A4 (ru) |
| JP (1) | JP2002532079A (ru) |
| CA (1) | CA2347734A1 (ru) |
| WO (1) | WO2000035483A1 (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6969601B2 (en) | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| CA2380979A1 (en) * | 1999-08-13 | 2001-02-22 | Brigham And Women's Hospital, Inc. | Inhibitors of the lectin complement pathway (lcp) and their use |
| WO2002006460A2 (en) * | 2000-07-13 | 2002-01-24 | Jens Christian Jensenius | Masp-2, a complement-fixing enzyme, and uses for it |
| EP1186299A1 (en) | 2000-09-12 | 2002-03-13 | Universitair Medisch Centrum Utrecht | The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system |
| US20060140939A1 (en) * | 2003-02-21 | 2006-06-29 | Fung Sek C M | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| PT2374819T (pt) | 2003-05-12 | 2017-07-04 | Helion Biotech Aps | Anticorpos para masp-2 |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| US8524453B2 (en) | 2006-02-10 | 2013-09-03 | The Brigham And Woman's Hospital, Inc. | Lectin complement pathway assays and related compositions and methods |
| JP2010505946A (ja) | 2006-10-10 | 2010-02-25 | アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム | 神経再生改善のための補体阻害 |
| MX344322B (es) | 2009-10-16 | 2016-12-13 | Omeros Corp | Uso de una composición que comprende un agente inhibidor de masp-2 efectivo para inhibir o prevenir la aparición de agregados en la vaculatura de un sujeto que sufre de un desorden de coagulación mediado por complemento. |
| NZ603581A (en) | 2010-06-19 | 2015-05-29 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
| NZ746139A (en) | 2011-04-08 | 2023-11-24 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR101641057B1 (ko) | 2011-05-04 | 2016-07-20 | 오메로스 코포레이션 | Masp-2 의존적 보체 활성화를 억제하는 조성물 |
| WO2014144763A2 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan Kettering Cancer Center | High affinity anti-gd2 antibodies |
| CN108588033B (zh) * | 2018-04-24 | 2021-09-24 | 富恩生物技术（成都）有限公司 | 杂交瘤细胞株、cd31单克隆抗体、制备方法及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270199A (en) | 1987-08-20 | 1993-12-14 | The Children's Medical Center Corporation | Human mannose-binding protein |
| DE3856180T2 (de) * | 1987-08-20 | 1998-09-03 | Childrens Medical Center | Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren |
| DE3927723A1 (de) * | 1989-01-26 | 1990-08-02 | Ulrich Prof Dr Speck | N - acetylglucosamin zur buccalen anwendung |
| WO1991006010A1 (en) * | 1989-10-11 | 1991-05-02 | Institute Of Child Health | Diagnostic procedure |
| AU3881493A (en) * | 1992-03-19 | 1993-10-21 | University Of British Columbia, The | Method and composition for suppression of side effects of anti-inflammatory drugs |
| JPH06121695A (ja) * | 1992-10-13 | 1994-05-06 | Fuji Yakuhin Kogyo Kk | 抗ヒトマンノース結合蛋白モノクローナル抗体およびその利用 |
| JPH07238100A (ja) * | 1994-02-25 | 1995-09-12 | Sumitomo Electric Ind Ltd | ヒトのｍａｓｐに対するモノクローナル抗体 |
| US5998173A (en) * | 1996-02-20 | 1999-12-07 | The University Of Bristish Columbia | Process for producing N-acetyl-D-glucosamine |
-
1999
- 1999-12-15 JP JP2000587802A patent/JP2002532079A/ja active Pending
- 1999-12-15 EP EP99967362A patent/EP1140171A4/en not_active Withdrawn
- 1999-12-15 CA CA002347734A patent/CA2347734A1/en not_active Abandoned
- 1999-12-15 WO PCT/US1999/029919 patent/WO2000035483A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002532079A5 (ru) | ||
| JP4716350B2 (ja) | 潜伏期膜タンパク質に対する抗体およびそれらの使用 | |
| JP2022104941A (ja) | ヒト化抗ｃｄ７３抗体 | |
| DK2298348T3 (en) | Antibody-binding alpha4Beta7 integrin and its use in the treatment of inflammatory bowel disease | |
| Yang et al. | Differential expression of CD8 epitopes amongst porcine CD8‐positive functional lymphocyte subsets | |
| RU2006115835A (ru) | Человеческие антитела против человеческого 4-1вв (cd137) | |
| JP2002511424A5 (ru) | ||
| EP1001021B1 (en) | Monoclonal antibody to human CD21, and its uses | |
| RU2009103533A (ru) | Способы получения поликлональных антител, антисыворотка, содержащая поликлональные антитела, и способы иммунизации | |
| CA2381706C (en) | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof | |
| JP2004517611A5 (ru) | ||
| WO2019051164A1 (en) | ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH | |
| US20020155109A1 (en) | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 | |
| KR20080059449A (ko) | 치료용 약제 | |
| JP2010501164A5 (ru) | ||
| US5480974A (en) | Antibodies to human C5a receptor | |
| JP2005505256A5 (ru) | ||
| CA2343579A1 (en) | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists | |
| JPH08504170A (ja) | 進行性免疫抑制症患者の評価と治療 | |
| AU665783B2 (en) | Anti-alpha6-integrin-antibodies | |
| Blanco et al. | The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression | |
| EP0672130A1 (en) | Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors | |
| JP2018532427A (ja) | 抗ｃｄ９５ｌ抗体 | |
| JP2003523735A5 (ru) | ||
| JP2003523735A (ja) | ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体 |